Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

23 jun 2013 8:30 a.m. - 27 jun 2013 12:45 p.m.

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

Session Chair(s)

Sir Martin  Landray, PHD, FRCP

Sir Martin Landray, PHD, FRCP

Chief Executive

Protas, United Kingdom

Learning Objective : Discuss the workshops on quality risk management; Describe general principles for building quality into the design of trials; Identify benefits and obstacles to the adoption of this approach based on feedback from CTTI workshop participants.

Speaker(s)

Sir Martin  Landray, PHD, FRCP

What Are the Key Drivers for Quality?

Sir Martin Landray, PHD, FRCP

Protas, United Kingdom

Chief Executive

Mark  Behm

Quality Risk Assessment and Quality by Design: Principles Not Jargon

Mark Behm

Astrazeneca, United States

Sr Director Procedural Quality

Ann  Meeker-O'Connell, MS

Regulatory Requirement for Ensuring Quality: A US Perspective

Ann Meeker-O'Connell, MS

Novartis, United States

Executive Director, Monitoring Excellence Head

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.